Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615001230549
Ethics application status
Approved
Date submitted
4/11/2015
Date registered
10/11/2015
Date last updated
17/10/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
The effectiveness of pre-travel health advice on illness rates in Western Australians returning from Bali, Indonesia.
Scientific title
In Western Australians travelling to Bali, Indonesia, does pre-travel health advice (compared to no pre-travel health advice) lower the rate of illness?
Secondary ID [1] 287786 0
none
Universal Trial Number (UTN)
none
Trial acronym
none
Linked study record

Health condition
Health condition(s) or problem(s) studied:
travel-related communicable disease symptoms 296672 0
Condition category
Condition code
Infection 296897 296897 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention will be a short (~two minute) animated video containing health information specific to Bali/Southeast Asia. Potential areas of interest will include; foodborne illness (e.g. ‘bali belly), mosquito borne illness (e.g. dengue, chikungunya), rabies (avoiding monkey and canine contacts), and measles (checking vaccination status). This video will be complemented by written information below the video.

A link to this video will be emailed out in the intervention participants, and will be viewed no less than one month before the participant departs for Bali. This is to allow the participant sufficient time to check vaccinations ect.
The adherance will be monitored by a video heatmap: a graphical representation of a single viewing session. For each viewer it will show the specific interaction the viewer
had, including when/where was it watched, which portion was skipped and which portion was watched again. Next to each heatmap the percentage of the video that viewers have watched will be displayed.
Intervention code [1] 293177 0
Prevention
Comparator / control treatment
The control group will be recruited the same way as the intervention group, but will not receive any PTHA from this project, and this group will determine the baseline of illness in returning travellers.
Control group
Active

Outcomes
Primary outcome [1] 296508 0
The primary objective is to determine the rate of communicable disease symptoms in Western Australian travellers to Bali, Indonesia, and to ascertain if an online pre travel health advice (PTHA) intervention has any effect on this rate.

The survey builds upon an airport pre-departure survey that was administered to WA travellers in 2014. It will be focus group tested in late 2015.
Timepoint [1] 296508 0
This will be assessed with a post travel survey within 2-weeks of the participants return from Bali.
Secondary outcome [1] 318629 0
To assess the effectiveness of an online PTHA intervention on communicable disease symptom rates in Bali travellers.
This differs from the primary outcome, as the primary outcome will determine if standard PTHA from the currently available sources (GP, smarttraveller.org, travel clinic ect.) is effective in reducing communicable disease rates. The first secondary outcome will focus solely on the PTHA intervention developed by researchers for this project.
The survey builds upon an airport pre-departure survey that was administered to WA travellers in 2014. It will be focus group tested in late 2015.
Timepoint [1] 318629 0
This will be assessed with a post travel survey within 2-weeks of the participants return from Bali.
Secondary outcome [2] 318661 0
To estimate the economic cost of illness in Bali travellers.

The survey builds upon an airport pre-departure survey that was administered to WA travellers in 2014. It will be focus group tested in late 2015.
Timepoint [2] 318661 0
This will be assessed with a post travel survey within 2-weeks of the participants return from Bali.
Secondary outcome [3] 318732 0
To assess if an online pre-travel health advice intervention effects the health risk knowledge in Western travellers returning from Bali.

The survey builds upon an airport pre-departure survey that was administered to WA travellers in 2014. It will be focus group tested in late 2015.
Timepoint [3] 318732 0
This will be assessed with a post travel survey within 2-weeks of the participants return from Bali.
Secondary outcome [4] 318733 0
To determine the incidence of communicable disease symptoms in Western Australians returning from Bali.
The survey builds upon an airport pre-departure survey that was administered to WA travellers in 2014. It will be focus group tested in late 2015.
Timepoint [4] 318733 0
This will be assessed with a post travel survey within 2-weeks of the participants return from Bali.
Secondary outcome [5] 318734 0
To determine if a traveller’s health behaviours and health risk perception affect their rate of communicable disease symptoms.

The survey builds upon an airport pre-departure survey that was administered to WA travellers in 2014. It will be focus group tested in late 2015.
Timepoint [5] 318734 0
This will be assessed with a post travel survey within 2-weeks of the participants return from Bali.
Secondary outcome [6] 318735 0
To determine what other factors may influence the incidence of communicable disease symptoms in Western Australians returning from Bali.

The survey builds upon an airport pre-departure survey that was administered to WA travellers in 2014. It will be focus group tested in late 2015.
Timepoint [6] 318735 0
This will be assessed with a post travel survey within 2-weeks of the participants return from Bali.

Eligibility
Key inclusion criteria
Potential participants must be Australian residents, travelling to Bali, staying in Bali for at least one night, over the age of 18, departing and returning within the 12-month research period, able and willing to give consent and complete the survey.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Persons under the age of 18 and non-Australian residents will be excluded from the study.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The participants will be allocated a random number by computer algorythm from an array when signing up on the consent page. This will be done via mailchimp's API system when importing the data from the online form into a mailchimp list. Using this number as a selection crieria, the participants will be segmented into two groups.

All participants will receive almost identical communications from the study, the only difference will be a link to the pre-travel health advice video included in the intervention groups communications. this video will not be accessible to those outside of the intervention group.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

The people administering the treatment/s

Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The project objectives are:
1. Is an online pre-travel health advice intervention effective in reducing the incidence of communicable disease symptoms and improving health risk knowledge in Western travellers returning from Bali?
2. Does the incidence of communicable disease symptoms in Western Australians returning from Bali differ by whether or not they have sought PTHA?
3. What is the incidence of communicable disease symptoms in Western Australians returning from Bali?
4. Does a traveller’s health behaviours and health risk perception affect their rate of communicable disease symptoms?
5. What other factors may influence the incidence of communicable disease symptoms in Western Australians returning from Bali?
6. What is the economic cost of communicable disease symptoms in Western Australians returning from Bali?


Data analysis will be carried out using EpInfo, a data analysis tool downloaded from the CDC (Centers for Disease Control and Prevention, Atlanta), and Stata Statistical Software.
In order to meet the six stated aims, this project will apply two study designs to the data analysis; combining a randomised control, and prospective cohort study.

Prospective cohort study: objective 2-6.
The control group (those participants recruited into the study who have not received the intervention on-line PTHA) from the randomised control trial, will make up the cohort for the second study design; a prospective cohort study. The proportions who received PTHA from a source other than this study, the source of this travel advice and differences in demographic groups will be compared between travellers who fell ill (objective 2). Data from the control group will also be used to determine the cumulative incidence of communicable disease symptoms in travellers returning from Bali (objective 3). Using a logistic regression analysis, the survey data on demographics, risk prevention behaviours and knowledge will be analysed to determine any factors resulting in an increased risk of communicable disease symptoms in this study population (objectives 4 and 5). Data from this group will also be used for the economic cost-of-illness analysis (objective 6).

Randomised control study: objective 1.
A randomised control design will be used to determine the effectiveness of the online PTHA intervention (objective 1). The proportion of travellers who fell ill will be compared between the control and intervention groups. This analysis will be carried out using Pearson’s chi-square test for comparison of disease symptom rates and a T-test for comparison of mean risk prevention knowledge. A logistic regression analysis will be performed with presence of communicable disease symptoms (yes/ no) as the dependent outcome and the intervention (yes/no) as the main exposure. Other variables such as external PTHA will be adjusted for in this model.

Sample size calculation
Objective 1 and 2 seek to determine whether an online PTHA intervention or external PTHA respectively, lower the rate of communicable disease symptoms in Western Australians returning from Bali. Existing literature suggests that 22-64% of travellers fall ill whilst travelling, and that a reduction in illness when visiting a travel doctor before travelling is ~20%. Therefore the sample size calculation assumed an illness rate of 40% in the non-exposed participants, with a reduction of 10% in the exposed participants (those who sought PTHA of their own volition) detected at 80% power with a p value of 0.05. A sample size of 712 participants completing the study; 356 exposed and 356 unexposed, was calculated using PS Power and Sample Size statistical software. Assuming ~50% are lost the follow up (the average for internet based trials), at least 1,424 participants; 712 exposed and 712 unexposed would need to enrol in the study.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/09/2016
Actual
28/09/2016
Date of last participant enrolment
Anticipated
31/08/2017
Actual
1/10/2017
Date of last data collection
Anticipated
Actual
1/10/2017
Sample size
Target
1424
Accrual to date
Final
2395
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 292318 0
Government body
Name [1] 292318 0
Western Australian Department of Health
Country [1] 292318 0
Australia
Primary sponsor type
Government body
Name
Western Australian Department of Health
Address
227 Stubbs Terrace, Shenton Park WA 6008
Country
Australia
Secondary sponsor category [1] 290998 0
None
Name [1] 290998 0
none
Address [1] 290998 0
none
Country [1] 290998 0
Other collaborator category [1] 278692 0
University
Name [1] 278692 0
The University of Western Australia
Address [1] 278692 0
The University of Western Australia
35 Stirling Highway
Perth WA 6009
Country [1] 278692 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 293790 0
Western Australian Department of Health Human Research Ethics Commitee
Ethics committee address [1] 293790 0
Ethics committee country [1] 293790 0
Australia
Date submitted for ethics approval [1] 293790 0
22/09/2015
Approval date [1] 293790 0
16/02/2016
Ethics approval number [1] 293790 0
2015/58
Ethics committee name [2] 295744 0
The University of Western Australia Health Human Research Ethics Committee
Ethics committee address [2] 295744 0
Ethics committee country [2] 295744 0
Australia
Date submitted for ethics approval [2] 295744 0
18/02/2016
Approval date [2] 295744 0
22/02/2016
Ethics approval number [2] 295744 0
RA/4/1/8110

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 61326 0
Miss Chloe Thomson
Address 61326 0
Department of Health
Communicable Disease Control Directorate
Grace Vaughan House
227 Stubbs Terrace, Shenton Park
WA 6008
Country 61326 0
Australia
Phone 61326 0
+61 8 9388 4865
Fax 61326 0
Email 61326 0
[email protected]
Contact person for public queries
Name 61327 0
Chloe Thomson
Address 61327 0
Department of Health
Communicable Disease Control Directorate
Grace Vaughan House
227 Stubbs Terrace, Shenton Park
WA 6008
Country 61327 0
Australia
Phone 61327 0
+61 8 9388 4865
Fax 61327 0
Email 61327 0
[email protected]
Contact person for scientific queries
Name 61328 0
chloe thomson
Address 61328 0
Department of Health
Communicable Disease Control Directorate
Grace Vaughan House
227 Stubbs Terrace, Shenton Park
WA 6008
Country 61328 0
Australia
Phone 61328 0
+61 8 9388 4865
Fax 61328 0
Email 61328 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.